Medical tool supplier Danaher (DHR) is expanding its product offerings by purchasing British biotech firm Abcam Plc (ABCM) for $5.7 billion, including debt.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Mirxes, a Singapore-headquartered developer of RNA-based tests for the early detection of cancer and other diseases, said this week that it has recently signed two agreements that will help advance the company's commercial push into China and Indonesia.

Agilent Technologies Inc. (NYSE: A) today announced the issuing of a companion diagnostic (CDx) Class C IVDR certification for PD-L1 IHC 22C3 pharmDx, Code SK006. This CDx assay has previously been CE-IVD–marked for sales in the European Union and is now certified in accordance with the new EU Regulation for in vitro diagnostic medical devices (IVDR).

Thermo Fisher Scientific said on Thursday that its Exent Solution, an automated mass spectrometry system for diagnosing patients with monoclonal gammopathies, including multiple myeloma, has been approved under Europe's In Vitro Diagnostics Regulation.

LumiraDx Limited (NASDAQ: LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its second quarter ended June 30, 2023.

The Alzheimer’s disease blood test developer C2N Diagnostics has released a new version of its screener for beta amyloid proteins, and it’s gearing up for a nationwide rollout as public hopes rise for treatments that may make some headway against the condition.

Medtronic (MDT.N) on Tuesday raised its annual profit forecast as the return of non-urgent surgery volumes to pre-pandemic levels boosted demand for its medical devices, sending its shares up 3%.

Not long after acquiring Resolution Bioscience in a deal worth more than half a billion dollars, Agilent Technologies has resolved to shutter the business, which was developing liquid biopsy tests that were powered by next-generation sequencing technology and meant to be used as companion diagnostics for cancer patients.

Geneseeq Technology Inc. has announced that three of our next-generation sequencing (NGS)-based cancer genetic testing kits, GENESEEQPRIME NGS Tumor Gene Detection Kit (GeneseeqPrime ™), GENESEEQ Homologous Recombination Deficiency Detection Kit (GeneseeqPrime™ HRD), and GENESEEQ Blood Cancer Gene Detection Kit (Hemasalus™ DNA/Hemarna™ RNA), have obtained the European Union’s CE Mark approval.

China Association of In Vitro Diagnostics (CAIVD) and In Vitro Diagnostics Society of China Association for Medical Devices Industry jointly compiled this report.

A new blood test is being developed to improve ovarian cancer diagnosis, with the potential to reduce unnecessary surgery leading to better health outcomes, saving time, stress and money for patients as well as the healthcare system.

To accelerate access to diagnostics in the continent, Africa CDC in partnership with key partners have launched the Africa Collaborative Initiative to Advance Diagnostics (AFCAD).

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

South Korean next-generation sequencing-based diagnostic firm NGeneBio said on Friday that it has entered a collaboration agreement with Chinese sequencing platform company MGI Tech to expand the commercial access of NGeneBio's cancer testing products.